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OBJECTIVES: To compare informal caregiver burden of caregivers providing care to 
elderly individuals with and without Parkinson’s disease (PD) and estimate costs 
associated with providing informal care to elderly individuals with and without 
PD. METHODS: A retrospective cross-sectional study was conducted using National 
Alliance for Caregiving, American Association of Retired Persons (NAC/AARP) survey 
(2004, 2009). Adults (age ≥ 18 years) with no formal caregiving training, who provided 
help with at least one activity of daily living or instrumental activity of daily living 
were classified as informal caregivers. The care-recipients were elderly (age ≥ 65 
years) individuals with and without PD. Caregiver burden was measured (scale of 
1[low] - 5[high]) based on three questions on physical strain, emotional stress and 
financial hardship on the caregivers. Costs associated with informal care were esti-
mated by multiplying number of informal caregiver hours per week by the median 
wage ($10.10/hour) of a household aide (2013 US$). Mean differences in caregiver 
burden and costs were evaluated with t-tests. Multiple linear regressions were con-
ducted to compare caregiving burden and costs among individuals with and without 
PD. RESULTS: The mean caregiver burden was similar among caregivers of individu-
als with and without PD (2.25 vs. 2.21). Although not statistically significant, the 
average number of caregiving hours per week for care-recipients with PD was higher 
(27.51 hours, 95% CI: 14.4- 41.2) than those without PD (19.73 hours, 95% CI: 18.3- 
21.2). The average costs of informal caregiving for care-recipients with and without 
PD were approximately $14,448 and $11,355 respectively. Multivariate analyses did 
not show significant differences in caregiver burden and costs. CONCLUSIONS: No 
significant differences in caregiver burden and costs were observed among caregiv-
ers of care-recipients with and without PD. Appropriate interventions are needed 
to reduce number of hours of informal caregiving, which may lead to decrease in 
overall informal caregiver burden.
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OBJECTIVES: Approximately 1/3 of patients with partial-onset seizures (POS) are 
drug resistant and frequently require adjunctive treatment (Brodie 2012). Although 
adjunctively-treated patients are identified in claims data by the concurrent admin-
istration of two or more AEDs, the minimum AED co-administration period has not 
been established. In order to avoid confounding in claims data analyses, the titration 
time to maintenance dose of AEDs used in adjunctive therapy needs to be carefully 
weighed in the classification of adjunctively-treated patients. This study sought 
to identify the impact of different co-administration periods on the proportion of 
patients identified as receiving adjunctive therapy within claims data. METHODS: 
This retrospective study used the HCMS employee database of commercially insured 
subjects. Subjects with POS [ICD9-CM= 345.4x,345.5x] between Jan-2001 and Jun-30-
2014 were identified from the employee’s spouses and assigned an index date based 
on their initial AED use. Subjects were required to have > 365 days of continuous 
eligibility following their index date. Patients were classified as having adjunctive 
therapy on the basis of having at least 30, 45, 60, or 90 days of concomitant AED 
use in the year following the index date. RESULTS: 350 eligible subjects married 
to employees were identified (69.5% female, 44.2 years old). The average time from 
their first POS diagnosis was 17.8 days for those initiating monotherapy, and 56.6 
days for those initiating adjunctive therapy; with progression from monotherapy 
to adjunctive therapy averaging 41.4 days. Percent classified receiving adjunctive 
therapy at 30, 45, 60, and 90-days were 41.7%, 39.1%, 38.3% and 34.9%, respec-
tively. CONCLUSIONS: Using a 90-day co-administration period, approximately 1 
in 3 POS subjects were classified as using adjunctive therapy. Researchers may find 
this consideration of different overlap periods useful for studies of AEDs requiring 
short vs. long titration periods.
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OBJECTIVES: To describe the changing landscape of disease modifying therapy 
(DMT) prescribing among treatment-naïve patients diagnosed with multiple scle-
rosis (MS) since the recent introduction of oral options. METHODS: Adult (≥ 18 
years) patients with a diagnosis of MS (ICD-9-CM 340) and ≥ 2 claims for an oral 
(fingolimod, teriflunomide, dimethyl fumarate) or non-oral (interferon beta-1a, 
interferon beta-1b, glatiramer acetate, natalizumab) DMT between March 29, 
2013 and February 1, 2014 (first prescription= index date) were identified in the 
Truven Health MarketScan® databases. Patients had ≥ 15 months of continuous 
enrollment (12 months pre- and 3 months post-index) with no DMT pre-index. 
Demographic and clinical characteristics were measured and compared at index 
and in the 12 month baseline period, respectively. RESULTS: A total of 3,221 
patients (mean age 46.5 years [SD= 11.6]; 75.2% female) met all study criteria. 
Approximately half (49.3%) of patients were prescribed an oral DMT. The most 
commonly prescribed DMT was dimethyl fumarate (38.2%), followed by glatiramer 
acetate (23.1%), natalizumab (8.9%) and intra-muscular interferon beta-1a (8.4%). 
Patients initiating treatment with an oral DMT were older (47.5 years [SD= 10.9] 
vs. 45.5 years [SD= 11.6]) and a higher proportion were prescribed symptomatic 
medications including antidepressants (39.1% vs. 32.2%), muscle relaxants (33.5% 
abstraction and who experienced ≥ 1 cluster within the 12 months prior to the 
abstraction were eligible. Demographics, comorbidities, and seizure-related medical 
information including treatments, rescue medication, and resource utilization over 
a 12-month period were abstracted by the neurologist using a web-based form. Costs 
were estimated from the literature and converted to 2013 US dollars. RESULTS: 
543 patient charts were collected; the mean patient age was 41 years and 58.7% 
were male. In this patient sample, 363 patients were utilizers of rescue medication 
(defined as those who consistently used rescue medication for every seizure cluster) 
and 180 were under-utilizers (not prescribed or failed to use rescue medication for at 
least 1 seizure cluster). Utilizers and under-utilizers experienced on average 2.4 and 
3.1 seizure clusters, respectively. Compared to utilizers, under-utilizers were more 
likely to progress to status epilepticus (25.0% vs. 15.4%, p< 0.01), visit an emergency 
department (56.7% vs. 45.2%, p= 0.012), and require hospitalization (41.1% vs. 25.6%, 
p< 0.01). Healthcare costs were significantly higher for under-utilizers than for uti-
lizers ($21,790 vs. $13,265, p= 0.038). CONCLUSIONS: In this study of adult patients 
with seizure clusters, under-utilizers of rescue medication had significantly higher 
seizure-related healthcare resource use and costs compared to utilizers of rescue 
medications. Supported by Acorda Therapeutics Inc.
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OBJECTIVES: Multiple sclerosis (MS) is a chronic, progressive disease. Mobility and 
walking impairment affect up to 90% of MS patients (Hemmett et al 2004). In clinical 
trials, walking impairment is often measured by walking speed (WS). The impact of 
walking impairment on direct and indirect healthcare resource utilisation (HCRU) 
and support resources, such as walking aids and home/workplace modifications, 
provides important information on burden of MS-related symptoms for health-
care decision makers. This analysis sought to investigate association between WS, 
measured by timed 25 foot walk test (T25FW), and direct HCRU, walking aid use and 
modifications to daily living at home and work. METHODS: Data were obtained 
from a cross-sectional 2014 study of 474 neurologists in France, Germany, Italy, 
Spain, UK and US. Neurologists completed 10-15 prospective records for consulting 
MS patients. Of the total 5538 MS patients, 737 had a T25FW score, and of these, 
320 returned a self-completion form reporting on the utilization of support ser-
vices. Mean age was 43.45 years. Mean time since diagnosis was 6.73 years. Logistic, 
Ordered Logistic, Negative Binomial and Probit (with sample selection) regressions 
assessed the relationship between WS and physician-reported data on direct 
patient HCRU and patient-reported data on walking aids and home and workplace 
modifications. Covariates were age, sex, body mass index, time since MS diagnosis 
and relevant concomitant conditions RESULTS: Reduced WS was associated with 
increased level of non-professional and professional caregiver need (p< 0.001), an 
increase in consultations with physiotherapists (p= 0.001) and urologists (p= 0.033) 
in the last 12 months, and increased visits to ER in the same timeframe (p= 0.010). 
Reduced WS was also associated with increased need for walking aids (p< 0.001) and 
home (p< 0.001), and workplace modification (p= 0.006). CONCLUSIONS: Reduction 
in WS is associated with increased HCRU and additional support requirements. 
Therapies that improve patients’ WS may be beneficial to reduce economic burden 
associated with reduced WS.
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BACKGROUND: While prior studies have supported clinical and health-related 
quality-of-life benefits of dalfampridine extended release tablets (D-ER; fampri-
dine outside the US, 10 mg twice daily) in persons with multiple sclerosis (MS), 
there are limited real-world data on economic benefits as measured by health-
care resource utilization. OBJECTIVES: To evaluate healthcare resource utiliza-
tion associated with D-ER. METHODS: Using the HealthCore Integrated Research 
DatabaseSMof administrative claims from a large, geographically diverse, US 
population between 1/1/2009 and 2/28/2013, resource utilization was compared 
between patients with MS treated with D-ER versus not. Patients aged ≥ 18 years; 
with ≥ 2 pre-index MS-related medical or pharmacy claims and ≥ 12 months each 
of pre-index and post-index continuous enrollment; and without prior claims for 
D-ER and alternate gait-impairing etiologies were included. The D-ER cohort had 
≥ 1 D-ER claim from 1/1/2010 to 2/29/2012, while the cohort not receiving D-ER had 
≥ 1 medical claim(s) with a walking-attributable code (ICD-9-CM 781.2, 719.7, 781.0, 
781.3) and no D-ER use; in both cohorts the index date was the earliest relevant 
claim. The cohorts were propensity-score matched on baseline demographics, 
comorbidities, and MS-related resource utilization. Walking-attributable hospi-
talizations, emergency department (ED), neurologist office, and physical or occu-
pational therapy visits were compared from baseline to 1-year follow-up between 
cohorts. RESULTS: 958 propensity-score–matched patients (479 per cohort) were 
identified. Walking-attributable outcomes for total hospitalizations, measured as 
the change (follow-up minus baseline) between those on and not on D-ER, were 8 
and 31, respectively. Similarly, changes between cohorts in ED visits were –3 and 6; 
neurologist office visits, –52 and 354; and physical or occupational therapy visits, 
90 and 1474 respectively. There was a significant difference in utilization changes 
from baseline to follow-up between cohorts (P< .05). CONCLUSIONS: Results dem-
onstrated favorable walking-attributable resource utilization outcomes associated 
with D-ER treatment.
